Stockwinners Market Radar for January 12, 2025 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
TSLA... | Hot Stocks20:01 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) is exploring a bid to acquire Intra-Cellular Therapies (ITCI), a biopharmaceutical company focused on treatments for central nervous system disorders, Bloomberg's Michelle Davis and Dinesh Nair report, citing people familiar with the matter. Deliberations are ongoing and there's no certainty Johnson & Johnson will decide to pursue a deal, the people said. Other suitors could also emerge, they said. 2. Tesla (TSLA) has pocketed $11B from the sale of regulatory credits to rival automakers needing help to hit tough emissions targets -- easy money that could dry up if President-elect Trump rolls back Biden-era regulations, Axios' Joann Muller reports. In the nine months through September 2024, 43% of Tesla's $4.8B in net income came from selling regulatory credits to other carmakers, the author notes. Absent a change in policy, that revenue stream is likely to soar in coming years as legacy carmakers scramble to buy emissions credits from Tesla, which generates such credits with every vehicle it produces. 3. The Biden administration delayed until June an order for Nippon Steel (NPSCY) to abandon its $14.9B bid for U.S. Steel (X), the companies said on Saturday, giving them some time to revive the politically contentious deal, according to Reuters. President Joe Biden blocked the acquisition on national security grounds on Jan. 3, and Treasury Secretary Janet Yellen said this week the proposed deal had received a "thorough analysis" by the interagency review body, the Committee on Foreign Investment in the United States. 4. Shares of Constellation Energy (CEG), the country's largest owner of nuclear plants, jumped 25% on the news Friday that it will buy Calpine, a privately held owner of natural-gas plants and geothermal power. Investors clearly like that proposition, Avi Salzman writes in this week's edition of Barron's. At these levels, the better bet may be Vistra (VST), which owns both natural gas and nuclear assets. It will benefit from the same trends that are helping Constellation, and it offers a slightly less lofty entry point, the author notes. 5. Lionsgate's (LGF.B) "Den of Thieves: Pantera" won the weekend at the North American box office with a $15.5M debut. Moviegoing doesn't appear to be greatly impacted in the greater L.A. area by the devastating fires, according to The Hollywood Reporter, citing distribution sources monitoring the situation. Nonetheless, there was slowdown in some places, including at AMC Universal Citywalk and AMC Americana Glendale.
|
CRBU | Hot Stocks19:21 EST Caribou Biosciences initiates CB-010 GALLOP Phase 1 trial in lupus - Caribou Biosciences announced initiation of the GALLOP Phase 1 clinical trial evaluating CB-010 in patients with lupus nephritis and extrarenal lupus. In addition, Caribou highlighted successful execution across its three clinical-stage allogeneic CAR-T cell therapy programs in hematologic malignancies over the past year and provided an outlook on multiple clinical data catalysts planned for 2025. Regarding CB-010 ANTLER, Caribou plans to present data from both the additional 2L and prior CD19 relapsed LBCL patient cohorts in the first half of 2025. The company also plans to initiate a pivotal Phase 3 clinical trial in the second half of 2025 should data confirm the initial observation that partial HLA matching drives outcomes that are on par with autologous CAR-T cell therapies. Regarding CB-010 GALLOP, Caribou plans to provide updates as the GALLOP Phase 1 clinical trial in LN and ERL advances. Regarding CB-011 CaMMouflage, Caribou plans to present dose escalation data from the ongoing CaMMouflage Phase 1 clinical trial in r/r MM in the first half of 2025. Regarding CB-012 AMpLify, Caribou plans to provide updates on dose escalation as the AMpLify Phase 1 clinical trial in r/r AML advances.
|
AAPL | Hot Stocks08:40 EST Apple's board recommends shareholders vote against eliminating DEI programs - According to a proxy filling, Apple's board of directors recommended investors vote against a shareholder proposal to abolish the company's Diversity, Equity, and Inclusion programs. The proposal to abolish the company's "Inclusion & Diversity program, policies, department and goals" was submitted by the National Center for Public Policy, a conservative think tank.
|